Neurosteer's EEG system features a new representation of brain activity based on advanced EEG signal processing technology
NEW YORK, Nov. 4, 2022 /PRNewswire/ -- Neurosteer Inc. today announced the FDA approval of its Neurosteer® single-channel EEG brain monitoring platform. This authorization allows Neurosteer's discreet multipurpose system to be used in a wide range of clinical settings. In the ICU, it can offer continuous brain monitoring to support critical interventions. In a doctor's office, it can aid in the early detection of presymptomatic cognitive decline, including Alzheimer's, Parkinson's and dementia. And in drug trials, it can help in rapid and cost-effective mass screening of subjects who may have neurodegenerative disorders.
Neurosteer advances century-old EEG into the 21st century, using a strip of adhesive electrodes attached to a pocket-sized sensor that wirelessly transmits EEG data to the cloud for advanced signal processing. With a single adhesive forehead strip, Neurosteer's innovative solution delivers the traditional EEG frequency bands while being cleared by the FDA to include several novel visual representations of "brain metrics."
These brain metrics are based on Neurosteer's advanced signal processing technology and can help trained medical staff make neurological diagnoses. In addition, the placement of the adhesive strip on the forehead prevents hair interference, and the use of dry gel supports unattended operation for up to 12 hours. Finally, the system includes a non-invasive evaluation with auditory cues that can help in the early detection of brain deterioration.
Dr. Amitai Bickel, Surgeon at Western Galilee Hospital, commented, "After working with the Neurosteer EEG system for several years, I realized what an advantage it is to have a compact and easy-to-apply EEG brain monitor that can be used for real-time continuous monitoring. Neurosteer's innovative platform has the potential to revolutionize the standard of care in managing brain health."
Nathan Intrator, MD, Founder and CEO of Neurosteer, explained, "We are very pleased that the FDA has approved our affordable, portable EEG system and further recognized the potential clinical value of our visual representations of brain metrics. This This is an important step in achieving our goal of making brain monitoring and assessment widely available to all populations."
About the company
Neurosteer Inc. has developed an innovative brain monitoring platform based on a portable single channel EEG. It uses an adhesive strip of electrodes on the forehead connected to a pocket sensor that wirelessly transmits EEG data to the cloud for advanced signal processing. It complements traditional frequency band analysis with visual representations of "brain metrics". The company was founded in 2015 by Dr. Nathan Intrator to commercialize brain-monitoring technology that he initially developed at Tel Aviv University. With offices in New York, California and Israel, the company's proprietary product is currently being validated in clinical trials and used by pharmaceutical companies for patient screening and efficacy testing of new drugs.
Logo - enlaceFoto - enlace
View original content: enlace